The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018

(2018) Cornelia Liedtke et al.   Breast Care

The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER+/HER2−Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index

(2018) KINAN MOKBEL et al.   ANTICANCER RESEARCH

Gene-expression Profiling – A Decision Impact Analysis: Decision Dependency on Oncotype DX® as a Function of Oncological Work Experience in 117 Cases

(2018) CHRISTIAN EICHLER et al.   ANTICANCER RESEARCH

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer

(2017) Alberto Peláez-García et al.   PLoS One

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1

(2017) Johannes Ettl et al.   PLoS One

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

(2015) F Fitzal et al.   BRITISH JOURNAL OF CANCER

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

(2015) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test

(2012) Ralf Kronenwett et al.   BMC CANCER

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

(2012) Carsten Denkert et al.   VIRCHOWS ARCHIV

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

A New Look at Node-Negative Breast Cancer

(2011) N. Harbeck et al.   ONCOLOGIST

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

(2008) Giuseppe Viale et al.   JNCI-Journal of the National Cancer Institute